Resveratrol Possesses Protective Effects in a Pristane-Induced Lupus Mouse Model

Zhuo-Long Wang1,*, Xiao-Fang Luo1,*, Meng-Tao Li1,*, Dong Xu1, Shuang Zhou1, Hou-Zao Chen2, Na Gao1, Zhen Chen1, Ling-Ling Zhang1, Xiao-Feng Zeng1*

1. Department of Rheumatology, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing, China. 2. National Laboratory of Medical Molecular Biology, Institute of Basic Medical Science, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China

*zengxfpumc@gmail.com

These authors contributed equally to this work.

Abstract

Background: Systemic lupus erythematosus (SLE) is a multisystemic autoimmune disease characterized by the production of autoantibodies. To date, no therapy has been found to satisfactorily treat SLE. SIRT1 deficiency results in the development of an autoimmune syndrome in mice, including a high titer of anti-nuclear antibody in serum, immunoglobulin deposition in the kidney, and immune complex glomerulonephritis. Resveratrol is an activator of SIRT1 and possesses anti-inflammatory and immune-regulatory properties.

Objective: To evaluate the preventative effects of resveratrol on a pristane-induced lupus animal model and assess its putative immune modulation effects.

Methods: BALB/c mice received a single intraperitoneal injection of 0.5 ml of pristane on day 1 and then various doses of resveratrol were given to the mice daily starting on day 2 and continuing for seven months. The autoantibodies in serum and supernatants were measured. Single cells isolated from spleen, isolated CD4+ T cells, and CD19+ B cells were cultured with or without resveratrol in vitro and assessed by flow cytometry.

Results: Resveratrol attenuated proteinuria, immunoglobulin deposition in kidney, and glomerulonephritis as well as IgG1 and IgG2a in serum in pristane-induced lupus mice. Resveratrol also suppressed CD69 and CD71 expression on CD4+ T cells as well as CD4+ T cell proliferation, induced CD4+ T cell apoptosis, and decreased CD4 IFNγ+ Th1 cells and the ratio of Th1/Th2 cells in vitro. In vitro antibody production and proliferation of B cells were also inhibited.

Conclusion: Resveratrol possesses protective effects in pristane-induced lupus mice and may represent a novel approach for the management of SLE.
Introduction

Systemic lupus erythematosus (SLE) is a multisystemic autoimmune disease characterized by autoantibodies to components of the cell nucleus. Pathogenic autoantibodies are the primary cause of tissue damage in patients with SLE. Development of the disease is thought to arise due to genetic factors together with environmental triggers [1, 2, 3]. In addition, renal damage is the most important predictor of mortality [4]. However, despite intensive research, no therapy to date has been found to cure SLE, and those that adequately treat the disease may have severe and unfavorable side effects.

Several SLE animal models have been established and play an important role in investigating the mechanisms of the disease. One model is the pristane-induced lupus mouse model, which develops several autoantibodies and immune-complex glomerulonephritis [5, 6]. Studies have shown that these mice have disparate T cell requirements of two subsets of lupus-specific autoantibodies as well as the toll-like receptor 7 (TLR7)-dependent and FcγR-independent production of type I interferon [7, 8]. TLR7 is required for the production of autoantibodies and the development of murine lupus nephritis [9].

Several different elements of the immune system are potential targets for therapeutic intervention in patients with SLE [1, 10, 11]. Current therapeutics used to treat SLE, including glucocorticoids and cyclophosphamide (CTX), are directed at suppressing humoral immunity and the production of autoantibodies as well as helper T cells (Th) and B lymphocytes. In addition, a new generation of biological agents is currently under development; however, the long-term beneficial and adverse effects of such agents remain unknown [10, 11]. Therefore, more effective drugs with a favorable safety profile are urgently needed. Many natural compounds possess immune-modulatory effects and have the potential for treating autoimmune diseases, such as SLE. In this study, we assessed the efficacy of resveratrol for treating SLE.

Resveratrol (3,5,4-trihydroxystilbene) is a natural antimicrobial compound found in various plants and fruits [12, 13]. It has attracted great attention since the discovery of its cardioprotective properties several years ago [13, 14], and the compound has been shown to also possess anti-inflammatory, immune-regulatory, antioxidant, and blood fat-regulatory properties [13, 15]. Moreover, studies have shown that resveratrol can inhibit several experimental autoimmune diseases, including collagen-induced arthritis, encephalomyelitis, colitis, and diabetes, though the mechanisms are not fully understood [16, 17, 18, 19, 20].

Resveratrol is an activator of silent mating type information regulation 2 homolog 1 (SIRT1), which is a class III histone deacetylase [13]. SIRT1 deficiency results in the development of an autoimmune syndrome in mice that manifests as a high titer of anti-nuclear antibody in serum, immunoglobulin deposition in the kidney, and immune complex glomerulonephritis [21, 22].

It has been shown that resveratrol may modulate inflammatory genes and signaling transcription factors, including STAT3, NF-kB, AP-1, and Cyclooxygenase 2 (COX2), which play critical roles in SLE pathogenesis [13].
However, to date, the effects of resveratrol on SLE and pristane-induced lupus have not been explored. Therefore, in this study we evaluated whether resveratrol can prevent the development of pristane-induced lupus in a mouse model.

**Materials and Methods**

**Mice**

Female BALB/c mice that were 9-10-weeks-old were obtained from Weitonglihua, Ltd. (Beijing, China). All mice were housed at Peking University on a diurnal 12 h light/dark cycle. All experimental protocols described in this study were approved by the Ethical Committee for Animal Experimentation of Peking Union Medical College Hospital.

**Induction and treatment of pristane-induced lupus in mice**

Forty female BALB/c mice were randomly divided into the following four groups: (1) Resveratrol A group: 10 BALB/c mice received a single intraperitoneal (i.p.) injection of 0.5 ml of pristane (Sigma-Aldrich, USA) on day 1 and were fed with resveratrol (Sigma-Aldrich, USA) (50 mg/kg/d) daily starting on day 2 for seven months; (2) Resveratrol B group: 10 BALB/c mice received a single i.p. injection of 0.5 ml of pristane on day 1 and were fed with resveratrol (75 mg/kg/d) daily starting on day 2 for seven months; (3) Model control group: 10 BALB/c mice received a single i.p. injection of 0.5 ml of pristane on day 1 but were not given resveratrol; and (4) Normal control group: 10 BALB/c mice not injected with pristane and not fed with resveratrol.

**Proteinuria**

Proteinuria was measured on a 0–5+ scale using a colormetric assay strip for albumin (Gaoerbao limited, Guangzhou, China). The following scale was used for assessment: 0 = absent; 1+ = 10 mg/100 ml; 2+ = 30 mg/100 ml; 3+ = 100 mg/100 ml; 4+ = 300 mg/100 ml; and 5+ = ≥2000 mg/100 ml.

**ELISA**

Antibody concentrations were determined by ELISA. The anti-nuclear antibody (ANA), anti-ds-DNA, and anti-RNP/Sm antibodies were diluted 1:100 in murine serum. (ANA ELISA, Anti-ds-DNA ELISA, and Anti-nRNP/Sm ELISA, respectively; Euroimmun Medizinische Labordiagnosika AG, Germany). For ANA, the secondary antibodies were goat polyclonal anti-mouse IgG-Fc conjugated to horseradish peroxidase (HRP) (Abcam, USA) and goat polyclonal anti-mouse IgM-mu chain conjugated to HRP (Abcam, USA). For the anti-ds-DNA and anti-RNP/Sm antibodies, the secondary antibody was a goat polyclonal anti-mouse IgG-Fc conjugated to HRP (Abcam, USA). Assessment of supernatants and the determination of serum Ig isotypes were performed using the Mouse
Immunoglobulin Isotyping ELISA Kit (BD Biosciences, USA). IFN-α were
determined using the mouse IFN-alpha ELISA Kit (eBioscience, USA).

Cell culture and cell sorting
Mice were euthanized 7 months after receiving the single pristane injection and
spleens were removed for analysis. CD4+ T cells and CD19+ B cells from splenic
mononuclear cells (SMC) were purified by positive selection (Miltenyi Biotec,
Bergisch Gladbach, Germany). Cells were cultured in RPMI1640 medium
supplemented with 10% fetal bovine serum (FBS), 2 mM L-glutamine, and
100 U/mL penicillin-streptomycin. Cells were cultured at 37°C in a 5% CO2
incubator for the indicated time periods. SMCs and CD4+ T cells were activated
with ConA (Sigma-Aldrich, USA), anti-CD3 (BD Biosciences PharMingen, USA),
or anti-CD3/CD28 (BD Pharmingen, USA) with or without resveratrol (0, 10, 20,
40, or 80 μM) for the indicated time points. CD19+ B cells were activated with
lipopolysaccharide (LPS) with or without resveratrol (0, 10, 20, 40, or 80 μM).

CD69 and CD71
SMCs from pristane-induced lupus mice were activated with ConA (2.5 μg/ml),
anti-CD3 (1 μg/ml), or anti-CD3/CD28 (1 μg/ml) with or without resveratrol for
6–12 h (CD69) or 36–48 h (CD71) ex vivo. The cells were then stained with rat
anti-CD4-PerCP (BD Biosciences PharMingen, USA) and hamster anti-CD69-
FITC (BD Biosciences PharMingen, USA) or rat anti-CD71-FITC (BD
Biosciences, USA) to investigate the activation of CD4+ T cells by flow cytometry
(FACS Aria, BD Biosciences, USA).

Proliferation assay
Freshly isolated SMCs, CD4+ T lymphocytes, and CD19+ B lymphocytes were
labeled with Carboxyfluorescein Succinimidyl Ester (CFSE) (CFSE cell prolifera-
tion kit, Invitrogen, USA) and cultured under various conditions. Four days later,
the cells were analyzed by flow cytometry.

Apoptosis assay
Freshly isolated CD4+ T cells from the SMC fraction were cultured with or
without resveratrol for 36 h in vitro. The cells were then stained with Annexin V/
propidium iodide (PI) (Alexa Fluor 488 Annexin V and PI kit For Flow
Cytometry, respectively; Invitrogen, USA) to evaluate CD4+ T cell apoptosis by
flow cytometry.

Analysis of the helper T cell subpopulation
Freshly isolated SMCs were activated with phorbol-12-myristate-13-acetate
(PMA, Sigma-Aldrich, USA) and ionomycin (Sigma-Aldrich, USA) after having
been cultured with or without resveratrol for 2 h. The cells were then stained with anti-CD4-PerCP, anti-IL-4-PE (BD Biosciences, USA), anti-IFN-γ-APC (BD Biosciences, USA), and anti-IL-17-Alexa Fluor 488 (BD Biosciences, USA) to investigate Th1, Th2, and Th17+ cell populations by flow cytometry.

**Histology**

One kidney from each animal was fixed in 10% neutral-buffered formalin, cut into 5 µm-thick sections, and then stained with hematoxylin and eosin (H&E). Glomerular cellularity was evaluated by counting the number of nuclei per glomerular cross-section (30–40 glomerular cross-sections per mouse) after staining with hematoxylin and eosin. The other kidney from each animal was embedded in ornithine carbamoyltransferase and cut into 5-µm-thick sections for detecting IgG and IgM by direct immunofluorescence.

**Detection of IgG and IgM in renal tissue by immunofluorescence**

Freshly frozen sections (5 µm thick) were stained for IgG and IgM with goat polyclonal antibody anti-mouse IgG-H&L-FITC (1:80 dilution; Abcam, USA) or goat polyclonal anti-mouse IgM-H&L-FITC (1:80 dilution; Abcam, USA) antibody. Staining specificity was assessed using standard laboratory blocking and absorption procedures. No cross-reactivity of complement, fibrinogen, or glomerular tissues from controls was observed. The immunoglobulin deposition in kidney was scored as 0, 1+, 2+, 3+, or 4+.

**Statistical analysis**

Clinical scores were analyzed using the non-parametric Mann-Whitney U test and histological scores were assessed using the one-way analysis of variance (ANOVA) test. Other data were compared using the Student’s t-test or one-way ANOVA. The statistical significance of the various tests was examined by 2-sided hypothesis testing. P values <0.05 were considered statistically significant. Statistical analysis was performed using SPSS version 17.0 (SPSS, Chicago, IL, USA).

**Results**

1. **Protective effect of resveratrol in a pristane-induced lupus animal model**

1.1 **Proteinuria**

At the end of observation period, urinalysis revealed that the proteinuria of the normal control group was 0 or 1+, and 1+ to 3+ for the model control mice. The resveratrol A and resveratrol B groups had a lower proteinuria level compared to the model control group (Z=2.013; P=0.044; and Z=2.071; P=0.038, respectively; [S1 Table](#)). Therefore, resveratrol can prevent the development of proteinuria in this pristane-induced lupus model.
1.2 Histological pathogenesis
At the end of observation period, light microscopy of kidney sections revealed that 6 mice developed segmental or diffuse proliferative glomerular lesions with mononuclear cell infiltration among 10 model control mice (Fig. 1B): 3 mice among 10 resveratrol A group mice and 10 resveratrol B group mice, respectively. No mouse developed glomerular lesions among the normal control group mice. The mice from the resveratrol A group had a marked reduction in pathological lesions of the glomerulus compared to mice of the model control group (Fig. 1C) and slightly less lymphocyte infiltration was also observed. Similar results were detected in mice from the resveratrol B group as well (Fig. 1D).

The number of nuclei per glomerular cross-section, which is a measure of glomerular cellularity, was $39.3 \pm 4.1$ for mice in the normal control group. This value was decreased for mice in the resveratrol A and B groups compared to model control mice ($44.1 \pm 11.4$ vs. $52.1 \pm 14.6$, $t=2.282$, $p=0.027$; and $42.8 \pm 9.9$ vs. $52.1 \pm 14.6$, $t=2.510,p=0.017$, respectively). In contrast, there was no difference in glomerular cellularity between mice in the resveratrol A and B groups ($44.1 \pm 11.4$ vs. $42.8 \pm 9.9$, respectively; $t=0.441$, $p=0.661$).

1.3 Immunoglobulin G (IgG) and IgM deposition in kidney
At the end of the observation period, IgG deposition in kidney of normal control mice was negative, 0−2+ in model control mice, and 0−1+ in mice from the resveratrol A and B groups (Fig. 2A-D, S2 Table). Moreover, the extent of IgG deposition in the kidney of resveratrol A and B mice was significantly lower than that in the model control mice ($Z=2.294; p=0.022$; and $Z=2.294; p=0.022$, respectively; S2 Table). However, the IgG deposition in mice from the resveratrol A and B groups was not significantly different ($P>0.05$). Similar results were observed for IgM deposition (Fig. 2E-H; S3 Table). Taken together, these results indicate that resveratrol attenuates pristane-induced nephritis.

2. Resveratrol inhibits IgG1 and IgG2α in pristane-induced lupus
To assess the immune mechanisms responsible for the resveratrol-mediated prevention of ongoing pristane-induced lupus, we assessed its role in the regulation of humoral immunity by measuring total immunoglobulin levels and ANA as well as anti-ds-DNA and anti-RNP/Sm antibody levels in serum. At the end of the observation period, the IgG1 levels in mice from the resveratrol A group were significantly lower than those in the model control group ($2.08 \pm 0.04$ vs. $1.93 \pm 0.04$, respectively; $P<0.01$; Fig. 3A). Similar findings were observed for IgG2α levels between the two groups (Fig. 3B), but no differences were observed in IgG2b, IgG3, IgM, and IgA levels between the treatment and the model control groups (data not shown). Similar results were also detected in mice from the resveratrol B group (data not shown).

Throughout the observation period, ANA levels in mice from the resveratrol A and resveratrol B groups were lower than those in mice from the model control group, but the difference was not statistically significant ($0.74 \pm 0.32$ vs.
Fig. 1. Kidney pathology. The kidney sections were stained with hematoxylin and eosin (H&E) and representative images are shown. (A): Normal glomerulus from a normal control mouse (n = 10). (B): Proliferative glomerular lesions and mononuclear cell infiltration in glomerulus from a model control mouse (n = 10). (C): A marked reduction in pathological lesions in glomerulus from a mouse from the resveratrol A group (n = 10) (D): A marked reduction in pathological lesions is observed in glomerulus from a representative resveratrol B mouse (n = 10). (original magnification × 200)

doi:10.1371/journal.pone.0114792.g001

Fig. 2. Immunofluorescence microscopy. Glomerulus from a normal control mouse (A, E), model control mouse (B, F), resveratrol A mouse (C, G), and resveratrol B mouse (D, H). Panels A, B, C, and D were stained with goat polyclonal anti-mouse IgG-FITC and panels E, F, G, and H were stained with goat polyclonal anti-mouse IgM-FITC.

doi:10.1371/journal.pone.0114792.g002
0.57 ± 0.09, P = 0.137; and 0.74 ± 0.32 vs. 0.576 ± 0.23, P = 0.183, respectively, S1 and S2 Figures). Similar changes were also observed for anti-ds-DNA and anti-RNP/Sm antibodies.

3. IFN-α levels in serum
In light of the role of IFN-α in SLE, we analyse IFN-α in serum. At the end of observation period, IFN-α levels in mice from the resveratrol A and resveratrol B groups were lower than those in mice from the model control group, but the difference was not statistically significant (0.110 ± 0.011 vs. 0.115 ± 0.001, P = 0.330; and 0.111 ± 0.003 vs. 0.115 ± 0.001, P = 0.291, respectively.)

4. Resveratrol suppresses B lymphocyte proliferation and antibody production
Freshly isolated CD19+ B lymphocytes were cultured with LPS (10 μg/ml) and increasing concentrations of resveratrol (0, 10, 20, or 40 μM, respectively) for 4 d in vitro and then assessed for proliferation. Resveratrol significantly inhibited B cell proliferation (F = 49.56; p < 0.0001) compared to the controls in a concentration-dependent manner (Fig. 4A). To investigate the potential effect of resveratrol on B cells, purified B cells were cultured with LPS (10 μg/ml) with or without resveratrol (0, 20, 40, or 80 μM, respectively) for 7 d in vitro, and then Ig isotypes (IgG1, IgG2a, IgG2b, IgG3, IgM, and IgA) were measured in the supernatant. Compared to the controls, resveratrol significantly decreased the production of IgG1 (F = 10.923; P = 0.003), IgG2a (F = 16.001; P = 0.001), IgG2b (F = 16.934; P = 0.001), IgG3 (F = 20.167; p < 0.0001), IgM (F = 33.541; p < 0.0001), and IgA (F = 14.495; P = 0.001) (Fig. 4B).
5. Effects of resveratrol on CD4+ T lymphocyte in vitro

5.1 Resveratrol suppresses CD4+ T lymphocyte activation

Freshly isolated SMCs from pristane-induced lupus mice were activated with ConA (2.5 µg/ml) with or without resveratrol and the levels of CD69 and CD71 were then measured, which are markers of CD4+ T lymphocyte activation. The expression level of CD69 on CD4+ T lymphocytes was $3.28 \pm 1.33\%$ without activator, but when the cells were incubated with ConA and resveratrol (0, 10, 20, 40, or 80 µM), the levels increased to $81.88 \pm 6.98\%$, $75.04 \pm 14.19\%$, $72.60 \pm 9.28\%$, $62.98 \pm 12.02\%$, and $47.97 \pm 15.12\%$, respectively (Fig. 5A). Therefore, resveratrol significantly decreased the level of CD69 expression on CD4+ T lymphocytes activated with ConA in a dose-dependent manner. Moreover, a similar effect of resveratrol on CD4+ T lymphocytes was observed
when they were activated with anti-CD3 or anti-CD3/CD28 antibodies (Fig. 5B and C, respectively).

The expression level of CD71 on CD4+ T lymphocytes was 3.98 ± 2.92% without activator, but increased to 77.38 ± 10.87% when activated with ConA. However, the addition of 10, 20, 40, or 80 μM resveratrol decreased CD71 expression levels to 73.19 ± 12.94%, 69.05 ± 15.39%, 55.35 ± 19.82%, and 37.13 ± 23.67%, respectively, indicating that resveratrol significantly decreased the expression level of CD71 on CD4+ T lymphocytes activated with ConA in a dose-dependent manner (Fig. 5D). Similar effects were also observed when the cells were activated with anti-CD3 or anti-CD3/CD28 antibodies (Fig. 5E and F, respectively).
5.2 Resveratrol suppresses CD4+ T lymphocyte and SMC proliferation

Freshly isolated CD4+ T lymphocytes from pristane-induced lupus mice were activated with anti-CD3/CD28 antibodies (3 μg/ml) and interleukin-2 (IL-2) (200 U/ml) with or without resveratrol (0, 10, 20, 40, or 80 μM). We found that cell proliferation decreased after treatment with resveratrol in a dose-dependent manner (Fig. 5G). This dose-dependent reduction was also observed in SMCs activated with ConA (5 μg/ml) and treated with resveratrol compared to untreated control (Fig. 5H).

5.3 Resveratrol induces CD4+ T cell apoptosis

Freshly isolated CD4+ T cells were cultured with increasing concentrations of resveratrol for 36 h in vitro and then assessed for apoptosis. We found that treatment with 0, 10, 20, 40, or 80 μM resveratrol induced an apoptosis rate of 58.21 ± 2.33%, 61.25 ± 3.68%, 63.45 ± 2.05%, 68.40 ± 5.23%, and 72.56 ± 5.50%, respectively (Fig. 5I and Fig. 6).

5.4 Resveratrol reduces the percentage of Th1 cells and decreases the ratio of Th1/Th2 cells

Freshly isolated SMCs were activated with PMA and ionomycin after having been cultured with resveratrol (0, 20, 40, or 80 μM) for 2 h to investigate Th1, Th2, and Th17+ cell populations by flow cytometry. We found that CD4 IFNγ+ Th1 cells decreased after treatment with resveratrol in a dose-dependent manner (P<0.05; Fig. 7A), although resveratrol had no effect on CD4 IL-4+Th2 cells or CD4 IFNγ−IL-17+ Th17 cells (Fig. 7B, Fig. 7D, respectively). Importantly, we found that the ratio of Th1/Th2 cells (CD4 IL-4+Th2) decreased after treatment with resveratrol in a dose-dependent manner (P<0.05; Fig. 7C).

Discussion

SLE is an autoimmune disease that responds poorly to current therapy options in many cases. Our study showed for the first time that resveratrol can attenuate proteinuria, decrease IgG and IgM deposition in kidney, and reduce kidney histological lesions, suggesting that resveratrol can effectively prevent pristane-induced lupus in an animal model.

CD4+ T cells and B cells are intimately associated with SLE and pristane-induced lupus [1, 7, 23]. In humoral immunity, helper T cells interact with B lymphocytes and stimulate their proliferation and differentiation, resulting in the production of antibodies to components of the cell nucleus. Our results suggest that resveratrol has a profound inhibitory effect on CD4+ T cells and B cells. Moreover, we showed that resveratrol inhibits the activation of CD4+ T cells in vitro, similar to a previous report [24]. Our results also indicate that resveratrol inhibits the proliferation of CD4+ T cells and induces cellular apoptosis in vitro. More than half of the T cells were already apoptotic (Anexin V+PI−) in the absence of treatment with resveratrol in our study, which is related to the culture duration of up to 36 h in vitro. Indeed, it is known that the viability of T cells...
Fig. 6. Examples of dot plots showing apoptosis of CD4+ T cells in vitro. CD4+ T cells cultured with different concentrations of resveratrol. (A): CD4+ T cells cultured with 0 μM resveratrol. (B): CD4+ T cells cultured with 10 μM resveratrol. (C): CD4+ T cells cultured with 20 μM resveratrol. (D): CD4+ T cells cultured with 40 μM resveratrol. (E): CD4+ T cells cultured with 80 μM resveratrol.

doi:10.1371/journal.pone.0114792.g006

Fig. 7. The effect of resveratrol on the subset of T helper cells. (A): Resveratrol inhibits CD4 IFN-γ+ Th1 cells in a dose-dependent manner. (B): Resveratrol has no effect on CD4 IL-4+ Th2 cells. (C): Resveratrol decreases the ratio of Th1/Th2 cells in a dose-dependent manner. (D): Resveratrol had no effect on CD4 IFN-γ+IL-17+ Th17 cells. (mean ± SD; n=6, *: P<0.05).

doi:10.1371/journal.pone.0114792.g007
decreases as culture duration is prolonged\cite{25, 26}. In addition, resveratrol can inhibit the antibody production and proliferation of B cells \textit{in vitro}, which is consistent with previous reports \cite{27}.

Taken together, our results suggest that resveratrol has protective properties in a pristane-induced lupus animal model that appear to be attributed to its inhibitory effect on CD4+ T cells and B cells.

The detailed mechanisms responsible for resveratrol-mediated effects remain unclear, though it is postulated that the compound may inhibit CD4+ T cells through effects on SIRT1. Resveratrol is an activator of SIRT1, which is essential for maintaining T cell tolerance through AP-1 in mice \cite{21, 28}. Resveratrol-induced apoptosis may be mediated by Fas, Bcl-2, Bax, p53, or by depolarizing mitochondrial membranes and activating Caspase 9 \cite{29, 30, 31, 32}. Resveratrol induces growth arrest through activation of FOXO transcription factors in prostate cancer cells \cite{33} and suppresses the immune response through CD28/CTLA-4 and CD80 co-stimulatory pathways \cite{34}.

Antigen-presenting cells (APCs) present antigens to naive T cells during the recognition phase of immune responses to initiate these responses, and some APCs present antigens to differentiated T cells during the effector phase to trigger elimination of the antigens. Resveratrol can affect dendritic cell maturation and the antigen presentation capacity \textit{in vitro} \cite{35}. However, our results do not rule out a regulatory role of resveratrol in dendritic cells.

Inflammation that is induced by the deposition of antigen-Ab complexes in kidney is an important mechanism for the development of glomerular lesions. Resveratrol inhibits COX expression by suppressing NF-kappa B activation \cite{36} and also inhibits TNF-\textalpha-induced inflammation in fibroblasts by activating SIRT1 \cite{37}. The resveratrol-mediated suppression of inflammation may also be beneficial for reducing pristane-induced lupus glomerulonephritis.

Imbalance towards Th1 predominance is associated with acceleration of lupus-like autoimmune syndrome in MRL mice \cite{38}. Recent findings in lupus glomerulonephritis show that Th1 and Th17 cells have an essential role in the development of diffuse proliferative lupus nephritis and Th2 cytokines have an essential role membranous lupus nephritis \cite{39}. Our study found that CD4 IFN$\gamma^+$ Th1 cells, the ratio of Th1/Th2 cells, B cell, and Th1 cytokine promoting Ig (IgG2a, IgG3) decreased after treatment with resveratrol in a dose-dependent manner. Our findings suggest resveratrol may have effects for alleviating diffuse proliferative lupus nephritis. Resveratrol may also have effects for alleviating membranous lupus nephritis for it supressed Th2 cytokine promoting immunoglobulin (IgG1).

At the end of the observation period, ANA, anti-ds-DNA antibody and IFN-\textalpha levels in mice from the resveratrol treatment groups were lower than those in mice from the Model control group, but the differences were not statistically significant. The mechanism for this result remains unclear and will require further investigation through a well-designed study (including larger sample numbers) in the future.
Conclusions
In summary, our findings suggest that resveratrol has protective effects for alleviating pristane-induced lupus in mice and may represent a novel approach for managing SLE. Additional studies in other lupus models and well-designed clinical trials are needed to confirm these findings and explore its therapeutic effects in humans, respectively.

Supporting Information
S1 Figure. Comparison of serum antibodies at the end of the observation period. (A): ANA level in resveratrol treatment group is lower than that in the control group, but there is no significantly statistical difference (n=10 in each group). (B): Anti-ds-DNA level in resveratrol treatment group is lower than that in the control group, but there is no significantly statistical difference (n=10 in each group). (C): Anti-RNP/Sm antibody level in resveratrol treatment group is lower than that in the control group, but there is no significantly statistical difference (n=10 in each group).
doi:10.1371/journal.pone.0114792.s001 (TIF)
S2 Figure. Variation of serum ANA level in different time course.
doi:10.1371/journal.pone.0114792.s002 (TIF)
S1 Table. Comparison of proteinuria.
doi:10.1371/journal.pone.0114792.s003 (DOCX)
S2 Table. Comparison of IgG deposition in kidney.
doi:10.1371/journal.pone.0114792.s004 (DOCX)
S3 Table. Comparison of IgM deposition in kidney.
doi:10.1371/journal.pone.0114792.s005 (DOCX)

Acknowledgments
We thank Prof. Chengyu Jiang and Prof. Depei Liu for helpful discussion.

Author Contributions
Conceived and designed the experiments: Z-LW X-FL X-FZ. Performed the experiments: Z-LW X-FL M-TL DX SZ H-ZC NG ZC L-LZ. Analyzed the data: Z-LW X-FL X-FZ. Wrote the paper: Z-LW X-FL X-FZ.

References
1. Rahman A, Isenberg DA (2008) Systemic lupus erythematosus. N Engl J Med 358: 929–939.
2. Tsokos GC (2011) Systemic lupus erythematosus. N Engl J Med 365: 2110–2121.
3. Sestak AL, Nath SK, Sawalha AH, Harley JB (2007) Current status of lupus genetics. Arthritis Res Ther 9: 210.
4. Danila MI, Pons-Estel GJ, Zhang J, Vila LM, Reveille JD, et al. (2009) Renal damage is the most important predictor of mortality within the damage index: data from LUMINA LXIV, a multiethnic US cohort. Rheumatology (Oxford) 48: 542–545.

5. Satoh M, Reeves WH (1994) Induction of lupus-associated autoantibodies in BALB/c mice by intraperitoneal injection of pristane. J Exp Med 180: 2341–2346.

6. Satoh M, Kumar A, Kanwar YS, Reeves WH (1995) Anti-nuclear antibody production and immune-complex glomerulonephritis in BALB/c mice treated with pristane. Proc Natl Acad Sci U S A 92: 10934–10938.

7. Richards HB, Satoh M, Jennette JC, Okano T, Kanwar YS, et al. (1999) Disparate T cell requirements of two subsets of lupus-specific autoantibodies in pristane-treated mice. Clin Exp Immunol 115: 547–553.

8. Lee PY, Kumagai Y, Li Y, Takeuchi O, Yoshida H, et al. (2008) TLR7-dependent and Fc gammaR-independent production of type I interferon in experimental mouse lupus. J Exp Med 205: 2995–3006.

9. Savarese E, Steinberg C, Pawar RD, Reindl W, Akira S, et al. (2008) Requirement of Toll-like receptor 7 for pristane-induced production of autoantibodies and development of murine lupus nephritis. Arthritis Rheum 58: 1107–1115.

10. Monneaux F, Muller S (2009) Molecular therapies for systemic lupus erythematosus: clinical trials and future prospects. Arthritis Res Ther 11: 234.

11. Wallace DJ (2010) Advances in drug therapy for systemic lupus erythematosus. BMC Med 8: 77.

12. Pervaiz S (2003) Resveratrol: from grapevines to mammalian biology. FASEB J 17: 1975–1985.

13. Nakata R, Takahashi S, Inoue H (2012) Recent advances in the study on resveratrol. Biol Pharm Bull 35: 273–279.

14. Csiszar A, Labinskyy N, Olson S, Pinto JT, Gupte S, et al. (2009) Resveratrol prevents monocrotaline-induced pulmonary hypertension in rats. Hypertension 54: 668–675.

15. Bereswill S, Munoz M, Fischer A, Plickert R, Haag LM, et al. (2010) Anti-inflammatory effects of resveratrol, curcumin and simvastatin in acute small intestinal inflammation. PLoS One 5: e15099.

16. Xuzhu G, Komai-Koma M, Leung BP, Howe HS, McSharry C, et al. (2012) Resveratrol modulates murine collagen-induced arthritis by inhibiting Th17 and B-cell function. Ann Rheum Dis 71: 129–135.

17. Imler TJ, Petro TM (2009) Decreased severity of experimental autoimmune encephalomyelitis during resveratrol administration is associated with increased IL-17+IL-10+ T cells, CD4(−IFN-gamma cells, and decreased macrophage IL-6 expression. Int Immunopharmacol 9: 134–143.

18. Singh UP, Singh NP, Singh B, Hofseth LJ, Price RL, et al. (2010) Resveratrol (trans-3,5,4’-trihydroxystilbene) induces silent mating type information regulation-1 and down-regulates nuclear transcription factor-kappaB activation to abrogate dextran sulfate sodium-induced colitis. J Pharmacol Exp Ther 332: 829–839.

19. Cui X, Jin Y, Hofseth AB, Pena E, Habiger J, et al. (2010) Resveratrol suppresses colitis and colon cancer associated with colitis. Cancer Prev Res (Phila) 3: 549–559.

20. Milne JC, Lambert PD, Schenk S, Carney DP, Smith JJ, et al. (2007) Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature 450: 712–716.

21. Zhang J, Lee SM, Shannon S, Gao B, Chen W, et al. (2009) The type III histone deacetylase Sirt1 is essential for maintenance of T cell tolerance in mice. J Clin Invest 119: 3048–3058.

22. Sequeira J, Boily G, Bazinet S, Saliba S, He X, et al. (2008) sirt1-null mice develop an autoimmune-like condition. Exp Cell Res 314: 3069–3074.

23. Hoffman RW (2004) T cells in the pathogenesis of systemic lupus erythematosus. Clin Immunol 113: 4–13.

24. Zou T, Yang Y, Xia F, Huang A, Gao X, et al. (2013) Resveratrol Inhibits CD4+ T cell activation by enhancing the expression and activity of Sirt1. PLoS One 8: e75139.

25. Izawa T, Kondo T, Kurosawa M, et al. (2012) Fas-Independent T-Cell Apoptosis by Dendritic Cells Modulates Autoimmune Arthritis in MRL/lpr Mice. PLoS One 7: e48798.

26. M-X He, Y-W He (2013) A role for c-FLIPL in the regulation of apoptosis, autophagy, and necroptosis in T lymphocytes. Cell Death and Differentiation 20: 188–197.
27. Zunino SJ, Storms DH (2009) Resveratrol alters proliferative responses and apoptosis in human activated B lymphocytes in vitro. J Nutr 139: 1603–1608.

28. Kwon HS, Brent MM, Getachew R, Jayakumar P, Chen LF, et al. (2008) Human immunodeficiency virus type 1 Tat protein inhibits the SIRT1 deacetylase and induces T cell hyperactivation. Cell Host Microbe 3: 158–167.

29. Ko YC, Chang CL, Chien HF, Wu CH, Lin LI (2011) Resveratrol enhances the expression of death receptor Fas/CD95 and induces differentiation and apoptosis in anaplastic large-cell lymphoma cells. Cancer Lett 309: 46–53.

30. Roman V, Billard C, Kern C, Ferry-Dumazet H, Izard JC, et al. (2002) Analysis of resveratrol-induced apoptosis in human B-cell chronic leukaemia. Br J Haematol 117: 842–851.

31. Kuo PL, Chiang LC, Lin CC (2002) Resveratrol- induced apoptosis is mediated by p53-dependent pathway in Hep G2 cells. Life Sci 72: 23–34.

32. Dorrie J, Gerauer H, Wachter Y, Zunino SJ (2001) Resveratrol induces extensive apoptosis by depolarizing mitochondrial membranes and activating caspase-9 in acute lymphoblastic leukemia cells. Cancer Res 61: 4731–4739.

33. Chen Q, Ganapathy S, Singh KP, Shankar S, Srivastava RK (2010) Resveratrol induces growth arrest and apoptosis through activation of FOXO transcription factors in prostate cancer cells. PLoS One 5: e15288.

34. Sharma S, Chopra K, Kulkarni SK, Agrewala JN (2007) Resveratrol and curcumin suppress immune response through CD28/CTLA-4 and CD80 co-stimulatory pathway. Clin Exp Immunol 147: 155–163.

35. Svajger U, Obermajer N, Jeras M (2010) Dendritic cells treated with resveratrol during differentiation from monocytes gain substantial tolerogenic properties upon activation. Immunology 129: 525–535.

36. Surh YJ, Chun KS, Cha HH, Han SS, Keum YS, et al. (2001) Molecular mechanisms underlying chemopreventive activities of anti-inflammatory phytochemicals: down-regulation of COX-2 and iNOS through suppression of NF-kappa B activation. Mutat Res 480–481: 243–268.

37. Zhu X, Liu Q, Wang M, Liang M, Yang X, et al. (2011) Activation of Sirt1 by resveratrol inhibits TNF-alpha induced inflammation in fibroblasts. PLoS One 6: e27081.

38. Takahashi S1, Fossati L, Iwamoto M, Merino R, Motta R, et al. (1996) Imbalance towards Th1 predominance is associated with acceleration of lupus-like autoimmune syndrome in MRL mice. J Clin Invest 97: 1597–604.

39. Miyake K, Akahoshi M, Nakashima H (2011) Th subset balance in lupus nephritis. J Biomed Biotechnol 2011: 980266.